A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Kim, Hark Kyun ^a,b   Choi, Il Ju ^b   Kim, Chan Gyoo ^b   Kim, Hee Sung ^b   Oshima, Akira ^a   Michalowski, Aleksandra ^a   Green, Jeffrey E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; INITIATION FACTOR 4B; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN S6; PROTEIN TRAP1; RAD23A PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DNA REPAIR; DRUG EFFECT; DRUG EFFICACY; EMBRYO; EMBRYONIC STEM CELL; ENDOSCOPIC BIOPSY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MOLECULAR DYNAMICS; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSCRIPTION INITIATION; TREATMENT DURATION; TUMOR DIFFERENTIATION; UPREGULATION; ADENOCARCINOMA; CLINICAL TRIAL; CLUSTER ANALYSIS; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SCREENING; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; VALIDATION STUDY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; STOMACH NEOPLASMS;

EID: 79951986443     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016694     Document Type: Article

References (47)

1. Dean M, Fojo T, Bates S, (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5 (4): 275-284.
2. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24 (26): 4236-4244.
3. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE, (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3 (8): e3077-3092.
4. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, et al. Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy. Pharmacogenomics J In press.
5. Kang Y, Kang WK, Shin DB, Chen J, Xiong J, et al. (2006) Randomized phase III trial of capecitabine/cisplatin vs continuous infusion of 5-FU/cisplatin as first-line therapy in patients with advanced gastric cancer: efficacy and safety results. J Clin Oncol 24 (suppl; abstr 4018).
6. Miller AB, Hoogstraten B, Staquet M, Winkler A, (1981) Reporting results of cancer treatment. Cancer 47: 207-214.
7. Kim HK, Choi IJ, Kim HS, Kim JH, Kim E, et al. (2004) DNA microarray analysis of the correlation between gene expression patterns and acquired resistance to 5-FU/cisplatin in gastric cancer. Biochem Biophys Res Commun 316 (3): 781-789.
8. Simon R, Lam A, Li MC, Ngan M, Menenzes S, et al. (2007) Analysis of gene expression data using BRB-Array Tools, Cancer Informatics 2: 11-17.
9. Zhao F, Xuan Z, Liu L, Zhang MQ, (2005) TRED: a Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies. Nucleic Acids Research 33: D103-107.
10. Leung SY, Chen X, Chu KM, Yuen ST, Mathy J, et al. (2002) Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc Natl Acad Sci U S A 99 (25): 16203-16208.
11. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17 (6): 520-525.
12. Xu X, Zhao Y, Simon R, (2008) Gene sets expression comparison kit for BRB-ArrayTools. Bioinformatics 24: 137-139.
13. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, et al. (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40 (5): 499-507.
14. Assou S, Le Carrour T, Tondeur S, Ström S, Gabelle A, et al. (2007) A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells 25 (4): 961-973.
15. Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96-107.
16. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, et al. (2003) A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 100 (14): 8164-8169.
17. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122 (6): 947-956.
18. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, et al. (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125 (2): 301-313.
19. Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, et al. (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25: 2781-2791.
20. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, et al. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67 (13): 6325-6332.
21. Wu C, Wangpaichitr M, Feun L, Shi X, Fang J, et al. (2005) Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4 (1): 25-34.
22. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, et al. (2008) A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 7 (10): 3141-3149.
23. Ghayad SE, Bieche I, Vendrell JA, Keime C, Lidereau R, et al. (2008) mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci 99 (10): 1992-2003.
24. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, et al. (2007) Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12 (1): 81-93.
25. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, et al. (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22; 22 (21): 3205-3212.
26. Guo QM, Malek RL, Kim S, Chiao C, He M, et al. (2000) Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60 (21): 5922-5928.
27. Bair E, Tibshirani R, (2004) Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2 (4): E108.
28. Stingl J, Caldas C, (2007) Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 7 (10): 791-799.
29. Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, et al. (2009) TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett 279 (1): 39-46.
30. Rylova SN, Amalfitano A, Persaud-Sawin DA, Guo WX, Chang J, et al. (2002) The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res 62 (3): 801-808.
31. Chiang YY, Chen SL, Hsiao YT, Huang CH, Lin TY, et al. (2009) Nuclear expression of dynamin-related protein 1 in lung adenocarcinomas. Mod Pathol 22 (9): 1139-1150.
32. Chu G, Chang E, (1990) Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 87 (9): 3324-3327.
33. Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, et al. (1996) Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to Adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 56: 3577-3582.
34. Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, et al. (1998) Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chem Biol Interact 111-112: 187-198.
35. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, et al. (2008) Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2 (4): 333-344.
36. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, et al. (1999) Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 5 (9): 2588-2595.
37. Xie XK, Yang DS, Ye ZM, Tao HM, (2006) Recombinant antisense C-myc adenovirus increase in vitro sensitivity of osteosarcoma MG-63 cells to cisplatin. Cancer Invest 24 (1): 1-8.
38. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL, (2003) Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs 14 (1): 39-47.
39. Biroccio A, Benassi B, Fiorentino F, Zupi G, (2004) Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 6 (3): 195-206.
40. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, et al. (2005) Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23 (6): 1169-1177.
41. Huang CY, Beer TM, Higano CS, True LD, Vessella R, et al. (2007) Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 13 (19): 5825-5833.
42. Lee SC, Xu X, Chng WJ, Watson M, Lim YW, et al. (2009) Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer. Pharmacogenet Genomics 19 (11): 833-842.
43. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, et al. (2000) Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 60: 4403-4411.
44. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood 103: 2332-2336.
45. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, et al. (2008) Stem cell-related self-renewal signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26 (18): 3015-3024.
46. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, et al. (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3 (6): e2428-2440.
47. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, et al. (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8 (2): 310-314.